| July 23, 2014
Why Gilead isn't soaring
Gilead Sciences reported Q2 EPS of $2.36 ex-items on revenue of $6.53 billion, with $3.48 billion sales of Sovaldi. CNBC's Meg Tirrell reports the highlights from the conference call.
Sorry, we do not have a transcript available for this video at this time.